Radiation OncologyNCT06115811
Radiation Treatment Plan Evaluation Learning Tool Pilot Project
A study testing Radiation Treatment Plan Evaluation Learning Tool in people with Radiation Oncology, run by Massachusetts General Hospital at 1 site in United States.
Trial summary
This study involves both the development of a novel learning tool, the Radiation Treatment Plan Evaluation Learning Module, as well as a pilot program to validate this tool as an effective resource to teach treatment plan review and optimization to radiation oncology residents. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Radiation Oncology
- What is being tested?
- Radiation Treatment Plan Evaluation Learning Tool
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jun 2026to 1 Jul 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- The pilot program will be open to radiation oncology resident physicians that are in their PGY-2, PGY-3, or PGY-4 year.
- All residents must have completed a breast cancer-specific radiation oncology rotation at least 3 months prior to enrollment in the pilot program in order to be eligible.
Who cannot join
- -The study will not include any special populations.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02215
Rachel Jimenez, MD, 617-726-8651, RBJIMENEZ@PARTNERS.ORG
About this study
Official title: Development and Assessment of a Novel, Systematic Radiation Treatment Plan Evaluation Learning Tool for Radiation Oncology Residents
This study involves both the development of a novel learning tool, the Radiation Treatment Plan Evaluation Learning Module, as well as a pilot program to validate this tool as an effective resource to teach treatment plan review and optimization to radiation oncology residents.
Read the detailed description
This study involves both the development of a novel learning tool, the Radiation Treatment Plan Evaluation Learning Module, as well as a pilot program to validate this tool as an effective resource to teach treatment plan review and optimization to radiation oncology residents.
Stud procedures include screening for eligibility and completion of surveys and oncology examinations.
Participation is expected to last about 6-8 weeks.
It is expected about 20 radiation oncology resident physicians will participate in the study.
- Conditions
- Radiation Oncology
- Being tested
- Radiation Treatment Plan Evaluation Learning Tool
- Keywords
- Radiation Oncology, Education
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Radiation Treatment Plan Evaluation Learning ToolBehavioural
Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org.
| Study group | Role | What they receive |
|---|---|---|
| Radiation Treatment Plan Evaluation Learning Module | Experimental | Radiation oncology resident physicians will complete study procedures as below:
* Initial survey and pre-module examination.
* Learning module.
* Post-module survey and examination. Receives: Behavioral: Radiation Treatment Plan Evaluation Learning Tool |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Examination Score
Analyzed with a paired samples t-test.
Measured: Up to 8 weeks
Secondary outcomes (2)
Oncology Resident Confidence Rate
Scored using Likert scales and analyzed with non-parametric tests.
Measured: Week 1 - 8
Oncology Resident Perceived Competence Rate
Scored using Likert scales and analyzed with non-parametric tests.
Measured: Week 1 - 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2023
- Study start15 Jun 2026 (estimated)
- Primary completion15 Jun 2028 (estimated)
- Study completion1 Jul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Radiation OncologyStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rachel Beth Jimenez, Massachusetts General Hospital
- Investigators
- Rachel Jimenez, MD, Principal investigator, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06115811
- Sponsor's protocol ID
- 23-021
- Status last verified
- May 2026
- First submitted
- 30 Oct 2023
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Assessment of a Novel, Systematic Radiation Treatment Plan Evaluation Learning Tool for Radiation Oncology Residents
- ClinicalTrials.gov ID
- NCT06115811
- Acronym / sponsor ID
- 23-021
- Conditions
- Radiation Oncology
- Keywords
- Radiation Oncology, Education
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Study start
- 15 Jun 2026 (estimated)
- Primary completion
- 15 Jun 2028 (estimated)
- Study completion
- 1 Jul 2029 (estimated)
- First posted
- 3 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study involves both the development of a novel learning tool, the Radiation Treatment Plan Evaluation Learning Module, as well as a pilot program to validate this tool as an effective resource to teach treatment plan review and optimization to radiation oncology residents.
Detailed description
This study involves both the development of a novel learning tool, the Radiation Treatment Plan Evaluation Learning Module, as well as a pilot program to validate this tool as an effective resource to teach treatment plan review and optimization to radiation oncology residents.
Stud procedures include screening for eligibility and completion of surveys and oncology examinations.
Participation is expected to last about 6-8 weeks.
It is expected about 20 radiation oncology resident physicians will participate in the study.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Radiation Treatment Plan Evaluation Learning Module | Experimental | Behavioral: Radiation Treatment Plan Evaluation Learning ToolRadiation oncology resident physicians will complete study procedures as below: * Initial survey and pre-module examination. * Learning module. * Post-module survey and examination. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- The pilot program will be open to radiation oncology resident physicians that are in their PGY-2, PGY-3, or PGY-4 year.
- All residents must have completed a breast cancer-specific radiation oncology rotation at least 3 months prior to enrollment in the pilot program in order to be eligible.
Key exclusion criteria (1 listed)
- -The study will not include any special populations.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Radiation Treatment Plan Evaluation Learning ToolWeb-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org. | Behavioural | Radiation Treatment Plan Evaluation Learning Module |
Primary outcome
Objective Examination Score
Time frame: Up to 8 weeks
Analyzed with a paired samples t-test.
2 secondary outcomes
Oncology Resident Confidence Rate
Time frame: Week 1 - 8
Oncology Resident Perceived Competence Rate
Time frame: Week 1 - 8
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: Yes. The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Related trials for Radiation Oncology
RecruitingPhase 3
Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
Breast Cancer, Breast Reconstruction
Recruiting
Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients
Rectal Cancer, Radiation Oncology
RecruitingObservational study
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Oncology, Breast Cancer
RecruitingObservational study
Curatively Intended Thoracic Reirradiation
Radiotherapy Side Effect, Radiation Toxicity
RecruitingObservational study
Longitudinal Registry Including Patients Treated With Heavy Particles
Cancer, Oncology
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rachel Jimenez, MD principal investigator
Massachusetts General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Radiation Treatment Plan Evaluation Learning Tool in people with Radiation Oncology, run by Massachusetts General Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rachel Jimenez, MD (617-726-8651, RBJIMENEZ@PARTNERS.ORG), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective Examination Score (time frame: Up to 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026; AzTrials last refreshed its copy on 2 Nov 2026.